We retrospectively evaluated 410 patients with coinfection or cocolonization due to vancomycin-resistant (VR) enterococcus (VRE) and methicillin-resistant Staphylococcus aureus (MRSA). The prevalence rate was 19.8%. Risk factors included isolation of VR Enterococcus faecalis and use of linezolid or clindamycin. Inc18-like vanA plasmids were found in 7% of VR E. faecalis isolates and none of the VR E. faecium isolates.
The emergence of vancomycin resistance in Staphylococcus aureus, with 7 of 9 cases worldwide from southeast Michigan (12, 13) , is alarming. The isolation of enterococci containing the vanA gene identical to those of vancomycin-resistant (VR) S. aureus (VRSA) strains suggests that the vanA-mediated resistance was due to the transfer of an Inc18-type plasmid from VRE containing traA and repR genes to S. aureus (3, 5) . Accordingly, isolation of both VRE and methicillin-resistant S. aureus (MRSA) may be one of the foremost risk factors for the development of VRSA. The National Healthcare Safety Network report for 2006-2007 identified VRE and MRSA as the two most common antimicrobial-resistant pathogens associated with health care-associated infections (8) . Our study aimed to evaluate risk factors and epidemiology of colonization or infection with both VRE and MRSA. We also investigated the occurrence of traA and repR genes among VRE isolates to gain information on its potential role as a resistance mechanism for VRSA.
Microbiology records from a 900-bed tertiary-care facility in urban Detroit, MI, from January 2005 through December 2007 were reviewed for data from patients who had at least one culture positive for VRE. Cocolonization or coinfection with MRSA was defined as the isolation of at least one culture positive for MRSA within 14 days from the date of VRE isolation. Data from October to December 2007 included MRSA surveillance cultures. In vitro susceptibilities were determined by the clinical microbiology laboratory (4). PCR analysis was performed to detect the presence of traA and repR genes among VRE isolates (17 Table 1 . Table 2 lists the sources of the isolates, with skin or wounds being more significantly common for patients with both VRE and MRSA than for patients with VRE alone. VR E. faecalis rather than VR E. faecium was most commonly associated with cocolonization or coinfection with MRSA (35% versus 17.3%). The independent risk factors for VRE-MRSA cocolonization or coinfection are shown in Table 3 and include isolation of VR E. faecalis and prior receipt of linezolid or clindamycin in the last 90 days. traA and repR genes were found in 4 (7.02%) of the 57 VR E. faecalis isolates, and these genes were not found among VR E. faecium isolates. The 4 VR E. faecalis isolates were taken from blood (n ϭ 2), the urinary tract (n ϭ 1), and a surgical site (n ϭ 1). In this study, VRE-MRSA cocolonization or coinfection was common, occurring in 20% of all patients studied. Prior studies on cocolonization or coinfection with VRE and MRSA (1, 6, 7, 9, 11, 15) demonstrated prevalence rates ranging from 2.7% to 28.6% (6, 7, 10, 15) . We found the major risk factors for VRE and MRSA cocolonization or coinfection were isolation of VR E. faecalis, rather than E. faecium, and exposure to the antimicrobials linezolid and clindamycin. Earlier studies demonstrated different findings. Furuno et al. (7) showed age, admission to a medical intensive care unit, male gender, and receiving antimicrobial drugs on a previous admission within the preceding year as risk factors; Warren et al. (15) found age, hospitalization during the preceding 6 months, and admission to a long-term-care facility to be risks; and Polgreen et al. (11) reported residency in long-term-care facilities as a risk factor for both MRSA and VRE infections. Though vancomycin resistance was more common among E. faecium isolates, in this study, E. faecalis was independently associated with cocolonization or coinfection with MRSA. This finding has an important implication in a potential role of the organism in relation to VRSA isolation (3, 10) . The reason for linezolid and clindamycin being major risk factors is unclear and was not determined by the study. Both antimicrobial agents have anti-MRSA activity, and linezolid has in vitro activity against both enterococci and MRSA. Linezolid and clindamycin also inhibit protein synthesis and toxin production, which may have an impact on a virulence characteristic associated with colonization. With the recent rise in the use of linezolid, further studies are needed to determine a dynamic potential role in an interrelationship between VRE and MRSA. It remains a challenge to completely understand the relationship between the use of a specific agent and resistance and infections with resistant organisms. The Centers for Disease Control and Prevention advocate careful oversight of vancomycin use in the control of multidrug-resistant organisms (2) . Given the results of this study, in geographic areas where VRE and MRSA are endemic, additional monitoring and control of the use of linezolid and clindamycin may be of importance.
Our study is unique in determining the incidence of traA and repR genes among VRE in a geographic area known to have VRSA. The vanA VRE plasmid from the first VRSA isolate was identified as an Inc18-like plasmid (5, 16, 17) , which was related to the VRE vanA plasmids associated with the latter VRSA cases. The latter plasmids were characterized by the detection of the two Inc18-specific genes traA and repR (14, 17) . This study shows that Inc18-like vanA plasmids are rare among vancomycin-resistant E. faecalis and E. faecium isolates. (9, 12) . Limitations of our study include evaluation in a single hospital located in a metropolitan area. The VRE isolates examined for Inc18-like plasmids all originated in southeast Michigan. Limited data for the prevalence of traA and repR genes from other regions exist. VRE-MRSA coinfection or cocolonization was defined using a 14-day cutoff period, which could have missed subsequent MRSA cultures. As this is a retrospective study which used clinical cultures and surveillance MRSA cultures, we could have underestimated the true proportion of patients colonized with VRE and MRSA among selected patients.
Cocolonization or coinfection with VRE and MRSA was common in this study (20% prevalence). Independent risk factors include isolation of VR E. faecalis rather than E. faecium and prior use of linezolid or clindamycin. traA and repR genes, the roles of which remain unclear in the emergence of VRSA, are infrequent among VRE but were found in E. faecalis isolates. Patients who tested positive for the Inc18-like plasmids share similar characteristics with the VRSA cases. Infection prevention interventions for vancomycin-resistant E. faecalis may need particular attention. 
